Undisclosed financial conflicts of interest in DSM-5-TR: cross sectional analysis

Lauren C Davis,Alexa T Diianni,Sydney R Drumheller,Noha N Elansary,Gianna N D'Ambrozio,Farahdeba Herrawi,Brian J Piper,Lisa Cosgrove,Gianna N D’Ambrozio
DOI: https://doi.org/10.1136/bmj-2023-076902
2024-01-10
BMJ
Abstract:Abstract Objective To assess the extent and types of financial ties to industry of panel and task force members of the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders , fifth edition, text revision (DSM-5-TR), published in 2022. Design Cross sectional analysis. Setting Open Payments database, USA. Participants 92 physicians based in the US who served as members of either a panel (n=86) or task force (n=6) on the DSM-5-TR with information recorded in the Centers for Medicare and Medicaid Services Open Payments database during 2016-19. This period was chosen to include the year that development of the DSM-5-TR began and the three years preceding, a time consistent with previous research on conflicts of interest and consistent with the American Psychiatric Association’s disclosure requirements for the fifth revision (DSM-5) of the manual. Main outcome measures Type and amount of compensation the panel and task force members of DSM-5-TR received during 2016-19. Results After duplicate names had been removed, 168 individuals were identified who served as either panel or task force members of the DSM-5-TR. 92 met the inclusion criteria of being a physician who was based in the US and therefore could be included in Open Payments. Of these 92 individuals, 55 (60%) received payments from industry. Collectively, these panel members received a total of $14.2m (£11.2m; €13m). One third (33.3%) of the task force members had payments reported in Open Payments. Conclusions Conflicts of interest among panel members of DSM-5-TR were prevalent. Because of the enormous influence of diagnostic and treatment guidelines, the standards for participation on a guideline development panel should be high. A rebuttable presumption should exist for the Diagnostic and Statistical Manual of Mental Disorders to prohibit conflicts of interest among its panel and task force members. When no independent individuals with the requisite expertise are available, individuals with associations to industry could consult to the panels, but they should not have decision making authority on revisions or the inclusion of new disorders.
medicine, general & internal
What problem does this paper attempt to address?
The paper aims to explore the financial relationships between the members of the expert panel for the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) and the pharmaceutical industry. Specifically, the study's objective is to assess the types and amounts of financial support received by DSM-5-TR expert panel members from the industry between 2016 and 2019. ### Main Findings: - Out of the 92 expert panel members who met the inclusion criteria, 55 (60%) received payments from the industry. - These members received a total of over $14.2 million in payments. - One-third of the task force members had records of financial associations. ### Conclusion: The study indicates that conflicts of interest are prevalent among DSM-5-TR expert panel members. Given the significant influence of diagnostic and treatment guidelines, the standards for those involved in developing these guidelines should be very high. It is recommended to implement a rebuttable presumption against the participation of individuals with conflicts of interest in the decision-making process for the Diagnostic and Statistical Manual of Mental Disorders. If independent experts are lacking, individuals with industry associations may participate as advisors but should not have decision-making authority over the revision or addition of disorders. ### Research Background: - Previous studies have shown that financial associations with the industry were common among expert panel members for DSM-IV-TR and DSM-5. - This study utilized the U.S. Open Payments database, which has required all U.S. drug and device manufacturers to disclose payments to physicians and teaching hospitals since 2013. - The American Psychiatric Association had pledged to improve its management of financial conflicts of interest, but significant financial associations persisted during the development of DSM-5-TR. ### Discussion: - The impact of financial conflicts of interest on medical literature has been widely studied, including randomized controlled trials, meta-analyses, and clinical guidelines. - The study emphasizes the importance of transparency and suggests measures to reduce industry influence on the revision process of diagnostic manuals to ensure the fairness and evidence-based foundation of mental health practices.